Seres Therapeutics Inc. (NASDAQ:MCRB) has received an average recommendation of “Buy” from the nine ratings firms that are currently covering the stock. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $30.00.
MCRB has been the topic of a number of recent analyst reports. Cowen and Company initiated coverage on shares of Seres Therapeutics in a report on Monday, June 6th. They set an “outperform” rating on the stock. FBR & Co reiterated a “buy” rating on shares of Seres Therapeutics in a report on Friday, July 8th. Leerink Swann reiterated a “buy” rating and issued a $43.00 price objective on shares of Seres Therapeutics in a report on Thursday, July 14th. Zacks Investment Research downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 19th. Finally, HC Wainwright began coverage on shares of Seres Therapeutics in a report on Friday, July 29th. They issued a “buy” rating and a $50.00 price objective on the stock.
In other news, insider Michele Trucksis sold 38,064 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $35.14, for a total value of $1,337,568.96. Following the completion of the sale, the insider now owns 38,064 shares of the company’s stock, valued at $1,337,568.96. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Roger Pomerantz sold 88,211 shares of the business’s stock in a transaction dated Wednesday, July 6th. The shares were sold at an average price of $29.45, for a total transaction of $2,597,813.95. Following the completion of the sale, the chief executive officer now directly owns 236,468 shares of the company’s stock, valued at approximately $6,963,982.60. The disclosure for this sale can be found here. 41.90% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in MCRB. Birchview Capital LP acquired a new stake in shares of Seres Therapeutics during the second quarter worth about $145,000. Pacad Investment Ltd. purchased a new stake in Seres Therapeutics during the second quarter valued at $198,000. First Mercantile Trust Co. purchased a new stake in Seres Therapeutics during the second quarter valued at $229,000. GSA Capital Partners LLP purchased a new stake in Seres Therapeutics during the second quarter valued at $273,000. Finally, American International Group Inc. boosted its stake in Seres Therapeutics by 106.4% in the second quarter. American International Group Inc. now owns 10,262 shares of the company’s stock valued at $298,000 after buying an additional 5,290 shares in the last quarter. 78.28% of the stock is owned by institutional investors.
Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 3.66% during mid-day trading on Monday, reaching $11.84. 257,814 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $11.70 and its 200-day moving average is $23.58. Seres Therapeutics has a 52-week low of $8.05 and a 52-week high of $44.51. The stock’s market cap is $476.84 million.
Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, August 11th. The company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by $0.24. The company had revenue of $3 million for the quarter, compared to analyst estimates of $4.20 million. The company’s revenue was up NaN% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.45) EPS. On average, equities analysts expect that Seres Therapeutics will post ($2.33) EPS for the current year.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.